retatrutide phase 3 results october 2025 What caught my attention wasn't just the number. It was what the number represents. New trial data for showed an average weight loss of 28.3% at the highest dose Eli Lilly's Phase 3 clinical

However, hundreds of people taking the medications have reported pancreas-linked problems, prompting health officials to launch fresh research into the drugs side-effects

References Webber S

Their benefits now extend well beyond glycemic control and weight loss, with growing evidence supporting their use in the management of steatosis liver disease, obstructive sleep apnea, cardiovascular disease, and chronic kidney disease

Trial outcomes are useful, but they do not replace individualized care

Banatwala UESS, Health Science Reports (Vol

Retatrutide carries the same black box warning as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound)